Pharma Focus Europe

SUNOVION Launches KYNMOBI™ for the Treatment of Parkinson's Disease Off Episodes

Sunovion Pharmaceuticals Inc launched a novel drug KYNMOBI™ (apomorphine HCI) sublingual film (APL-130277) for the acute and intermittent treatment of off episodes in patients with Parkinson’s disease.

Parkinson’s disease is a chronic neurodegenerative disease, which is anticipated to affect 1.2 million Americans by 2030. It is expected that KYNMOBI is made effective in US pharmacies by September 2020.

KYNMOBI, a unique formulation of dopamine agonist apomorphine, which is supposed to be the first and only sublingual therapy acting rapidly for the treatment of OFF episodes patients associated with Parkinson’s disease. It can be used five times a day. Kynmobi, having ability to dissolve under the tongue helps people to loswer PD off symptoms.

KYNMOBI though a prescribed medicine useful for the treatment of Parkinson’s disease (PD) significantly have serious side effects such as nausea and vomiting, sleepiness or falling asleep during the day, dizziness, mouth (oral) irritation, hallucinations or psychotic behaviour, heart problems, fibrotic complications, falls and high fever.

According to the clinical studies, patients undergoing treatment with KYNMOBI medicine have resulted with significant improvements in motor symptoms at 30 minutes after dosing at week 12, with a mean reduction of 7.6 points, compared to other medicines such as placebo.

US Food and Drug Administration (FDA) has approved KYNMOBI™ (apomorphine HCI) sublingual film (APL-130277) for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD).

Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024